We recognise that these are preliminary observations but they highlight new areas for study to (i) identify the mechanistic basis of dystropathology in dysferlin-deficient muscles and (ii) gain further insight into the unexpected adverse effects of GCs in dysferlinopathy. The gene discussed is DYSF; the disease is neuromuscular disease caused by qualitative or quantitative defects of dysferlin.